Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), David P. Ryan(East Carolina University), Jeffrey A. Meyerhardt(CancerCare), Rebecca A. Miksad(Brigham and Women's Hospital), Thomas A. Abrams(Dana-Farber Cancer Institute), Charles S. Fuchs(University of Southern California), A. John Iafrate(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Kathryn R. Jors(New York University), Jeffrey W. Clark(Massachusetts General Hospital), Deborah Schrag(Dana-Farber Brigham Cancer Center), Eunice L. Kwak(Harvard University), Alona Muzikansky(Johns Hopkins University), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Hui Zheng(Harvard University)
Cited by 196
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k